Pharmacovigilance Data Analysis Using Information Coefficient
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacovigilance methods face challenges in efficiently analyzing vast volumes of data over long timeframes to derive and track trends in drug safety, particularly in identifying significant associations between drugs and adverse events, and in handling the complexity of drug interactions and co-morbid conditions.
Innovation Solution
A computer-implemented method for visualizing and analyzing pharmacovigilance data using a sample size-independent measure of association and statistical unexpectedness, based on an urn model, to detect significant associations between drugs and adverse events, incorporating demographic and clinical data, and displaying these findings in a graphical format to facilitate medical judgment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional pharmacovigilance methods are used to analyze drug safety data, then comprehensive safety evaluation can be performed, but the analysis becomes increasingly complex and time-consuming as data volume and timeframes expand
Solution Approach 1:
The patent transforms the analysis approach by changing key parameters: using information coefficient (IC) instead of traditional proportional reporting ratios, and employing natural logarithm transformations of drug and adverse event counts. These parameter changes enable the system to handle large volumes of post-market surveillance data efficiently while maintaining reliable safety signal detection, directly resolving the contradiction between evaluation reliability and analysis complexity
Solution Approach 2:
The patent replaces complex manual pharmacovigilance analysis methods with an automated computational system that calculates information coefficients and generates safety signals automatically. This substitution of mechanical/manual processes with automated computational mechanics enables comprehensive safety evaluation of vast datasets without proportionally increasing analytical complexity, as the system performs calculations systematically rather than through manual review
2Measurement precision
If detailed individual safety reports are analyzed to detect safety signals, then accurate adverse event detection is achieved, but the vast volume of data makes trend derivation and tracking difficult
Solution Approach 1:
The patent merges individual safety report data into aggregated statistical measures by calculating the information coefficient between drugs and adverse events based on their co-occurrence patterns in the database. This combining of individual reports into collective statistical signals maintains precise adverse event detection while dramatically improving analysis efficiency, as the system evaluates aggregated IC values rather than processing each individual report separately
Solution Approach 2:
The patent introduces a new dimensional approach by using the information coefficient as a statistical measure that captures the strength of association between drugs and adverse events across the entire dataset. This additional statistical dimension enables efficient trend tracking and pattern recognition across vast volumes of data while maintaining the precision needed for accurate safety signal detection
3Reliability
If statistical methods are applied to determine causal relationships between drugs and adverse events, then safety signal detection is improved, but the interpretation becomes more challenging for medical experts
Solution Approach 1:
The patent introduces the information coefficient as an intermediary statistical measure that bridges raw safety data and expert interpretation. The IC provides a standardized, quantifiable measure of association strength between drugs and adverse events that is both statistically rigorous and intuitively interpretable by medical experts, facilitating easier understanding of safety signals while maintaining reliable detection capabilities
Solution Approach 2:
The patent employs visual presentation methods to enhance the interpretability of statistical results for medical experts. By presenting information coefficients and safety signals in visually distinct formats that highlight the strength and significance of associations, the system makes complex statistical findings more accessible and easier to interpret clinically, without compromising the reliability of safety signal detection
Data Source
AI summary
A computer-implemented method of analyzing a dataset of pharmacovigilance data, includes determining a sample size-independent measure of association between two conditions of interest in the dataset of pharmacovigilance data; using a hypergeometric distribution to determine a measure of statistical unexpectedness between the conditions of interest in said dataset, wherein the distribution is based on an urn model under a hypothesis that the conditions are statistically independent; and displaying the measure of association with the measure of the statistical unexpectedness to identify a significant association between conditions of interest.